The earnings call for Merck & Co., Inc. reveals a mixed bag of results and guidance for the fourth quarter and full year 2006. The company reported a 3% increase in revenue, driven by strong sales of new products like Gardasil and Januvia, despite patent expirations and challenges in the VIOXX litigation. The company also reaffirmed its 2007 guidance, expecting earnings per share of $2.51 to $2.59, excluding restructuring charges. However, the stock may face short-term pressure due to the uncertainty around the VIOXX litigation and the expected increase in legal defense costs. Additionally, the company's focus on cost management and strategic growth in new markets may provide long-term opportunities. Overall, the stock is likely to face short-term pressure due to the uncertainty around the VIOXX litigation and the expected increase in legal defense costs.

Rating: -1